Showing 1 to 12 of 30 results
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following pressure from Republican attorneys general and concerns about its expanded telehealth access, despite decades of evidence supporting its safety.
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following pressure from Republican attorneys general and concerns about its expanded telehealth access, despite decades of evidence supporting its safety.
Progress
28% Bias Score
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
Progress
40% Bias Score
Numan Secures $60M to Expand Telehealth Services and Develop AI Hub
British telehealth company Numan, founded by Sokratis Papafloratos, raised $60 million—$30 million in equity from Big Pi Ventures and others, and $27 million in debt from HSBC—to expand into Greece and establish an AI/ML hub focused on digital health, following a year of significant growth.
Numan Secures $60M to Expand Telehealth Services and Develop AI Hub
British telehealth company Numan, founded by Sokratis Papafloratos, raised $60 million—$30 million in equity from Big Pi Ventures and others, and $27 million in debt from HSBC—to expand into Greece and establish an AI/ML hub focused on digital health, following a year of significant growth.
Progress
12% Bias Score
AI Foot Scanner Detects Worsening Heart Failure 13 Days Before Hospitalization
A new AI-powered foot scanner, developed by Heartfelt Technologies, can detect worsening heart failure up to 13 days before hospital admission, potentially improving patient outcomes and reducing healthcare costs.
AI Foot Scanner Detects Worsening Heart Failure 13 Days Before Hospitalization
A new AI-powered foot scanner, developed by Heartfelt Technologies, can detect worsening heart failure up to 13 days before hospital admission, potentially improving patient outcomes and reducing healthcare costs.
Progress
36% Bias Score
Online Connections Boost Wellbeing, Bridging Health Gaps
A study reveals that 90% of nbn users have connected online with friends or family in the last two years, with nearly half reporting feeling less lonely; online connections are beneficial for mental and physical wellbeing, bridging the health gap for older Australians and those in rural areas.
Online Connections Boost Wellbeing, Bridging Health Gaps
A study reveals that 90% of nbn users have connected online with friends or family in the last two years, with nearly half reporting feeling less lonely; online connections are beneficial for mental and physical wellbeing, bridging the health gap for older Australians and those in rural areas.
Progress
40% Bias Score
Trump Administration Moves to Dismiss Lawsuit Challenging Mifepristone Access
The Trump administration filed to dismiss a lawsuit from Idaho, Kansas, and Missouri seeking to restrict telehealth access to the abortion medication mifepristone, arguing the states lack legal standing and that their challenge to 2016 FDA actions is beyond the statute of limitations.
Trump Administration Moves to Dismiss Lawsuit Challenging Mifepristone Access
The Trump administration filed to dismiss a lawsuit from Idaho, Kansas, and Missouri seeking to restrict telehealth access to the abortion medication mifepristone, arguing the states lack legal standing and that their challenge to 2016 FDA actions is beyond the statute of limitations.
Progress
44% Bias Score
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following a letter from HHS Secretary Kennedy and FDA Commissioner Makary to Republican attorneys general, prompting concerns about potential restrictions on medication abortion access.
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following a letter from HHS Secretary Kennedy and FDA Commissioner Makary to Republican attorneys general, prompting concerns about potential restrictions on medication abortion access.
Progress
28% Bias Score
Australian Medicinal Cannabis Company Under Scrutiny for High-Volume Prescribing
A doctor at Australia's largest medicinal cannabis company, Montu, issued 72,000 prescriptions to 10,000 patients in two years, prompting concerns about unsafe prescribing practices and leading to investigations by federal health authorities; Montu initially denied but later confirmed the figures.
Australian Medicinal Cannabis Company Under Scrutiny for High-Volume Prescribing
A doctor at Australia's largest medicinal cannabis company, Montu, issued 72,000 prescriptions to 10,000 patients in two years, prompting concerns about unsafe prescribing practices and leading to investigations by federal health authorities; Montu initially denied but later confirmed the figures.
Progress
56% Bias Score
US Abortion Numbers Rise Despite State Bans
In 2024, a record 1.14 million abortions were performed in the US, despite bans in numerous states; this increase is largely due to telehealth abortions facilitated by "shield laws", while reported in-person abortions in states with total bans averaged only 30 per month.
US Abortion Numbers Rise Despite State Bans
In 2024, a record 1.14 million abortions were performed in the US, despite bans in numerous states; this increase is largely due to telehealth abortions facilitated by "shield laws", while reported in-person abortions in states with total bans averaged only 30 per month.
Progress
48% Bias Score
Decentralized Healthcare: An AI and Blockchain Solution to America's Chronic Disease Crisis
The US faces a chronic disease crisis costing $4.3 trillion annually, resulting in lower life expectancy. Decentralized care models using AI and blockchain offer a solution by enabling personalized interventions, secure data sharing, and continuous patient engagement, potentially reducing costs and ...
Decentralized Healthcare: An AI and Blockchain Solution to America's Chronic Disease Crisis
The US faces a chronic disease crisis costing $4.3 trillion annually, resulting in lower life expectancy. Decentralized care models using AI and blockchain offer a solution by enabling personalized interventions, secure data sharing, and continuous patient engagement, potentially reducing costs and ...
Progress
52% Bias Score
WeightWatchers Files for Bankruptcy, Pivots to Telehealth
WeightWatchers, facing declining revenue and an aging customer base, filed for Chapter 11 bankruptcy on Tuesday to eliminate \$1.15 billion in debt, planning to focus on its telehealth division, WeightWatchers Clinic, which saw a 57% revenue increase in the last year, and expects to exit bankruptcy ...
WeightWatchers Files for Bankruptcy, Pivots to Telehealth
WeightWatchers, facing declining revenue and an aging customer base, filed for Chapter 11 bankruptcy on Tuesday to eliminate \$1.15 billion in debt, planning to focus on its telehealth division, WeightWatchers Clinic, which saw a 57% revenue increase in the last year, and expects to exit bankruptcy ...
Progress
32% Bias Score
HIMS Stock Surges 23% on Wegovy Partnership
Hims & Hers Health (HIMS) stock surged 23% on April 29th after Novo Nordisk announced it would offer its weight-loss drug Wegovy through HIMS's platform, significantly boosting HIMS's revenue potential due to its large subscriber base and the high price of Wegovy.
HIMS Stock Surges 23% on Wegovy Partnership
Hims & Hers Health (HIMS) stock surged 23% on April 29th after Novo Nordisk announced it would offer its weight-loss drug Wegovy through HIMS's platform, significantly boosting HIMS's revenue potential due to its large subscriber base and the high price of Wegovy.
Progress
48% Bias Score
Showing 1 to 12 of 30 results